Lung Cancer

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment.

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations.

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.

Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.

A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.

A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC.

Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.

Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRAS^G12C-mutated NSCLC subtypes.